decisionhealth Newsletters, Answer Books - 2009 Issue 3 (March)
Anti-Kickback Advisory Opinion Summaries / 2006 OIG Advisory Opinions / Opinion 06-21 - OIG Rules on Another PAP Program
Subscribe or sign in to view the full article.
Article Overview
This summary explains an OIG advisory opinion addressing a drug manufacturer patient assistance program for patients enrolled in Medicare Part D. It focuses on the program structure, financial-need-based eligibility, cost-sharing, recordkeeping, notification to Part D plans, and the anti-kickback/fraud-and-abuse concerns the agency evaluated. The article is relevant to compliance, pharmacy, reimbursement, and health care legal teams reviewing assistance-program design for federally insured patients.
Why This Topic Matters
Manufacturer assistance programs can affect beneficiary cost-sharing, benefit utilization, and federal program exposure. Understanding the compliance considerations in an OIG advisory opinion helps organizations evaluate whether a patient assistance model raises anti-kickback or Medicare payment concerns.
What You Will Learn
- How an OIG advisory opinion framed a manufacturer patient assistance program for Medicare Part D beneficiaries.
- What broad safeguards were discussed in connection with fraud-and-abuse risk.
- Which compliance themes matter when a patient assistance program interacts with federal drug coverage.
- How the opinion addressed financial-need eligibility, duration of assistance, and program recordkeeping at a high level.
Who Should Read This
- Compliance officers
- Medical coders
- Billing staff
- Pharmacy benefit managers
- Health care attorneys
- Revenue cycle professionals
- Drug manufacturer compliance teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com